Trials / Unknown
UnknownNCT05723432
KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of KD6001 in Combination With Anti-PD-1 Antibody in Patients With Advanced Melanoma
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- Sponsor
- Shanghai Kanda Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of KD6001 in combination with toripalimab in patients with advanced melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KD6001 | KD6001 will be administered intravenously. |
| DRUG | Toripalimab | Toripalimab will be administered intravenously. |
Timeline
- Start date
- 2023-03-22
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
- First posted
- 2023-02-10
- Last updated
- 2023-04-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05723432. Inclusion in this directory is not an endorsement.